Induced pluripotent stem cells (iPSCs) are poised to play a pivotal role in cell therapy, providing a versatile starting material for generating therapeutic cells and offering the potential for personalized medicine. Their relevance is highlighted by the growing need for timely provision of effective, off-the-shelf cell therapy solutions at a reasonable price point. The topic's timeliness is accentuated by advancements in gene editing, like CRISPR, which allow complex modifications to be introduced into iPSCs, providing differentiated progeny with new functionalities such as immune evasion and improved cell targeting.
A key challenge in iPSC application is the transition from research to clinical use, necessitating scalable manufacturing while maintaining quality and consistency. This includes ensuring genetic stability and developing cost-effective production methods. We will describe the trends in allogeneic cell manufacturing and how these techniques apply to iPSC production.
This presentation will describe the current state of iPSC development and manufacture, and how new allogeneic manufacturing capabilities may be applied to iPSCs. Overcoming the challenges to iPSC manufacturing will revolutionize treatment approaches, ushering in an era of off-the-shelf, effective medicine.